

B21

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/008603 A2

(51) International Patent Classification⁷: C12P 13/00
(21) International Application Number: PCT/EP02/07351
(22) International Filing Date: 3 July 2002 (03.07.2002)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
101 35 051.1 18 July 2001 (18.07.2001) DE
60/306,867 23 July 2001 (23.07.2001) US
(71) Applicant (for all designated States except US): DE-
GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düssel-
dorf (DE).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.
(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventor; and
(75) Inventor/Applicant (for US only): HERMANN, Thomas
[DE/DE]; Zirkonstrasse 8, 33739 Bielefeld (DE).
(74) Common Representative: DEGUSSA AG; Intellectual
Property Management, Patents and Trademarks, Location
Hanau, P.O.Box 13 45, 63403 Hanau (DE).

Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv)) for US only
Published:
— without international search report and to be republished
upon receipt of that report

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE
FAMILY WHICH CONTAIN AN ATTENUATED ASPA GENE



BEST AVAILABLE COPY

BEST AVAILABLE COPY

WO 03/008603 A2

The present invention relates to a process for the preparation of L-amino acids using strains of the Enterobacteriaceae family which contain an attenuated ASPA gene. The process comprises: a) selection of a nucleotide sequence which codes for this, in particular eliminated, by concentration of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Y

**Process for the Preparation of L-Amino Acids using Strains
of the Enterobacteriaceae Family which Contain an
Attenuated aspA Gene**

Field of the Invention

- 5 This invention relates to a process for the fermentative preparation of L-amino acids, in particular L-threonine, using strains of the Enterobacteriaceae family in which the aspA gene is attenuated.

Prior Art

- 10 L-Amino acids, in particular L-threonine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

- It is known to prepare L-amino acids by fermentation of
15 strains of Enterobacteriaceae, in particular *Escherichia coli* (*E. coli*) and *Serratia marcescens*. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the
20 stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

- 25 Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue α -amino- β -hydroxyvaleric acid (AHV), or are auxotrophic for
30 metabolites of regulatory importance and produce L-amino acid, such as e.g. L-threonine, are obtained in this

method.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of strains of the Enterobacteriaceae family which produce L-amino acids, by amplifying individual amino acid biosynthesis genes and investigating the effect on the production.

Object of the Invention

The object of the invention is to provide new measures for improved fermentative preparation of L-amino acids, in particular L-threonine.

Summary of the Invention

The invention provides a process for the fermentative preparation of L-amino acids, in particular L-threonine, using microorganisms of the Enterobacteriaceae family which in particular already produce L-amino acids and in which the nucleotide sequence which codes for the aspA gene is attenuated.

Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-arginine. L-Threonine is particularly preferred.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or a gene or allele which codes for a

weak promoter or a gene or allele which codes for a

3.

corresponding enzyme (protein) or gene, and optionally combining these measures.

By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.

The process comprises carrying out the following steps:

- 10 a) fermentation of microorganisms of the Enterobacteriaceae family in which the aspA gene is attenuated,
- b) concentration of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the Enterobacteriaceae family, and
- 15 c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.
- 20 The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. They are representatives of the Enterobacteriaceae family chosen
- 25 from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. Of the genus Escherichia the species Escherichia coli and of the genus Serratia the species Serratia marcescens are to be mentioned in particular.
- 30 Suitable strains, which produce L-threonine in particular, of the genus Escherichia, in particular of the species Escherichia coli, are, for example

- Escherichia coli TF427
Escherichia coli H4578
Escherichia coli KY10935
Escherichia coli VNIIGenetika MG442
5 Escherichia coli VNIIGenetika M1
Escherichia coli VNIIGenetika 472T23
Escherichia coli BKIIM B-3996
Escherichia coli kat 13
Escherichia coli KCCM-10132

- 10 Suitable L-threonine-producing strains of the genus
Serratia, in particular of the species Serratia marcescens,
are, for example

- Serratia marcescens HNr21
Serratia marcescens TLR156
15 Serratia marcescens T2000

- Strains from the Enterobacteriaceae family which produce L-threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of:
- 20 resistance to α -amino- β -hydroxyvaleric acid, resistance to
thialysine, resistance to ethionine, resistance to α -
methylserine, resistance to diaminosuccinic acid,
resistance to α -aminobutyric acid, resistance to
borrelidin, resistance to rifampicin, resistance to valine
analogues, such as, for example, valine hydroxamate,
25 resistance to purine analogues, such as, for example, 6-
dimethylaminopurine, a need for L-methionine, optionally a
partial and compensable need for L-isoleucine, a need for
meso-diaminopimelic acid, auxotrophy in respect of
threonine-containing dipeptides, resistance to L-threonine,
30 resistance to L-homoserine, resistance to L-lysine,
resistance to L-methionine, resistance to L-glutamic acid,
resistance to L-aspartate, resistance to L-leucine,
resistance to L-phenylalanine, resistance to L-serine,
resistance to L-cysteine, resistance to L-valine,
35 sensitivity to fluoropyruvate, defective threonine

dehydrogenase, optionally an ability for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feed back resistant form, enhancement
5 of homoserine kinase, enhancement of threonine synthase, enhancement of aspartate kinase, optionally of the feed back resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feed back resistant form,
10 enhancement of phosphoenol pyruvate synthase, enhancement of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the YfiK gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid formation.

15 It has been found that microorganisms of the Enterobacteriaceae family produce L-amino acids, in particular L-threonine, in an improved manner after attenuation, in particular elimination, of the aspA gene.

The nucleotide sequences of the genes of Escherichia coli
20 belong to the prior art and can also be found in the genome sequence of Escherichia coli published by Blattner et al. (Science 277: 1453 - 1462 (1997)).

The aspA gene is described, inter alia, by the following data:

25	Description:	Aspartate ammonium lyase (aspartase)
	EC No.:	4.3.1.1
	Reference:	Takagi et al.; Nucleic Acids Research 13(6): 2063-2074 (1985); Woods et al.; Biochemical Journal 237(2): 547-557 (1986); 30 Falzone et al.; Biochemistry 27(26): 9089- 9093 (1988); Jayasekera et al.; Biochemistry 36(30): 9145-9150 (1997)
	Accession No.:	AB000481

The nucleic acid sequences can be found in the databanks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA), the nucleotide sequence databank of the European Molecular
5 Biologies Laboratories (EMBL, Heidelberg, Germany or Cambridge, UK) or the DNA databank of Japan (DDBJ, Mishima, Japan).

The genes described in the text references mentioned can be used according to the invention. Alleles of the genes which
10 result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used.

To achieve an attenuation, for example, expression of the gene or the catalytic properties of the enzyme proteins can
15 be reduced or eliminated. The two measures can optionally be combined.

The reduction in gene expression can take place by suitable culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA
20 technique. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. The expert can find information in this respect, inter alia, for example, in Jensen and Hammer
25 (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier and Keasling (Biotechnology Progress 15: 58-64 (1999)), Franch and Gerdes (Current Opinion in Microbiology 3: 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook of
30 Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that of Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art. Examples which may be mentioned are the works of Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences, USA 95: 5511-5515 (1998)), Wentz and Schachmann (Journal of Biological Chemistry 266: 20833-20839 (1991)). Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as e.g. that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

Possible mutations are transitions, transversions, insertions and deletions. Depending on the effect of the amino acid exchange on the enzyme activity, "missense mutations" or "nonsense mutations" are referred to. Insertions or deletions of at least one base pair in a gene lead to "frame shift mutations", which lead to incorrect amino acids being incorporated or translation being interrupted prematurely. If a stop codon is formed in the coding region as a consequence of the mutation, this also leads to a premature termination of the translation. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

Suitable mutations in the genes, such as, for example, deletion mutations, can be incorporated into suitable strains by gene or allele replacement.

A conventional method is the method, described by Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)), of gene replacement with the aid of a conditionally replicating pSC101 derivative pMAK705. Other methods described in the prior art, such as, for example, those of Martinez-Morales et al. (Journal of Bacteriology 181: 1999, 7143-7148 (1999)) or those of Boyd et al. (Journal of Bacteriology 182: 842-847 (2000)), can likewise be used.

It is also possible to transfer mutations in the particular genes or mutations which affect expression of the particular genes into various strains by conjugation or transduction.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, with strains of the Enterobacteriaceae family, in addition to attenuation of the aspA gene, for one or more enzymes of the known threonine biosynthesis pathway or enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate or enzymes of glycolysis or PTS enzymes or enzymes of sulfur metabolism to be enhanced.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 5000%, based on total of the wild-type protein or on

activity or concentration of the protein in the starting microorganism.

Thus, for example, at the same time one or more of the genes chosen from the group consisting of

- 5 • the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
- the pyc gene of *Corynebacterium glutamicum* which codes for pyruvate carboxylase (WO 99/18228),
- 10 • the pps gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231(2): 332-336 (1992)),
- the ppc gene which codes for phosphoenol pyruvate carboxylase (Gene 31: 279-283 (1984)),
- 15 • the pntA and pntB genes which code for transhydrogenase (European Journal of Biochemistry 158: 647-653 (1986)),
- the rhtB gene which imparts homoserine resistance (EP-A-0 994 190),
- the mqo gene which codes for malate:quinone
20 oxidoreductase (WO 02/06459),
- the rhtC gene which imparts threonine resistance (EP-A-1 013 765),
- the thrE gene of *Corynebacterium glutamicum* which codes for the threonine export protein (WO 01/92545),
- 25 • the gdhA gene which codes for glutamate dehydrogenase (Nucleic Acids Research 11: 5257-5266 (1983); Gene 23: 199-209 (1983)),

- the hns gene which codes for the DNA-binding protein HLP-II (Molecular and General Genetics 212: 199-202 (1988)),
- 5 • the pgm gene which codes for phosphoglucomutase (Journal of Bacteriology 176: 5847-5851 (1994)),
- the fba gene which codes for fructose biphosphate aldolase (Biochemical Journal 257: 529-534 (1989)),
- 10 • the ptsH gene of the ptsHIcrr operon which codes for the phosphohistidine protein hexose phosphotransferase of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the ptsI gene of the ptsHIcrr operon which codes for enzyme I of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- 15 • the crr gene of the ptsHIcrr operon which codes for the glucose-specific IIA component of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- 20 • the ptsG gene which codes for the glucose-specific IIBC component (Journal of Biological Chemistry 261: 16398-16403 (1986)),
- the lrp gene which codes for the regulator of the leucine regulon (Journal of Biological Chemistry 266: 10768-10774 (1991)),
- 25 • the mopB gene which codes for 10 Kd chaperone (Journal of Biological Chemistry 261: 12414-12419 (1986)) and is also known by the name groES,
- the ahpC gene of the ahpCF operon which codes for the small sub-unit of alkyl hydroperoxide reductase
30 (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),

- the *ahpF* gene of the *ahpCF* operon which codes for the large sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences USA 92: 7617-7621 (1995)),
- 5 • the *cysK* gene which codes for cysteine synthase A (Journal of Bacteriology 170: 3150-3157 (1988)),
- the *cysB* gene which codes for the regulator of the *cys* regulon (Journal of Biological Chemistry 262: 5999-6005 (1987)),
- 10 • the *cysJ* gene of the *cysJIH* operon which codes for the flavoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
- the *cysI* gene of the *cysJIH* operon which codes for the
15 haemoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)) and
- the *cysH* gene of the *cysJIH* operon which codes for
20 adenylyl sulfate reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989))

can be enhanced, in particular over-expressed.

The use of endogenous genes is in general preferred.

"Endogenous genes" or "endogenous nucleotide sequences" are
25 understood as meaning the genes or nucleotide sequences present in the population of a species.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to attenuation of the *aspA* gene, for one or more of the genes
30 chosen from the group consisting of

12

- the tdh gene which codes for threonine dehydrogenase (Journal of Bacteriology 169: 4716-4721 (1987)),
- the mdh gene which codes for malate dehydrogenase (E.C. 1.1.1.37) (Archives in Microbiology 149: 36-42 (1987)),
- 5 • the gene product of the open reading frame (orf) yjfa (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the gene product of the open reading frame (orf) ytfP (Accession Number AAC77179 of the National Center for
10 Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the pckA gene which codes for the enzyme phosphoenol pyruvate carboxykinase (Journal of Bacteriology 172: 7151-7156 (1990)),
- the poxB gene which codes for pyruvate oxidase (Nucleic
15 Acids Research 14(13): 5449-5460 (1986)),
- the aceA gene which codes for the enzyme isocitrate lyase (Journal of Bacteriology 170: 4528-4536 (1988)),
- the dgsA gene which codes for the DgsA regulator of the phosphotransferase system (Bioscience, Biotechnology and
20 Biochemistry 59: 256-261 (1995)) and is also known under the name of the mlc gene,
- the fruR gene which codes for the fructose repressor (Molecular and General Genetics 226: 332-336 (1991)) and is also known under the name of the cra gene,
- 25 • the rpoS gene which codes for the sigma³⁸ factor (WO 01/05939) and is also known under the name of the katF gene,
- the aceB gene which codes for malate synthase A (Nucleic Acids Research 14(13): 5449-5460 (1986)),

- the aceK gene which codes for isocitrate dehydrogenase kinase/phosphatase (Journal of Bacteriology 170(1): 89-97 (1988)) and
- the ugpB gene which codes for the periplasmic binding protein of the sn-glycerol 3-phosphate transport system (Molecular Microbiology 2(6): 767-775 (1988))

to be attenuated, in particular eliminated or for the expression thereof to be reduced.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to attenuation of the aspA gene, to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed batch process (feed process) or the repeated fed batch process (repetitive feed process). A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as
5 e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.

- 10 Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be
15 used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus.

- 20 The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the above-mentioned substances.
25 Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

- Basic compounds, such as sodium hydroxide, potassium
30 hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable
35 substances having a selective action, e.g. antibiotics, can

be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 25°C to 45°C, and preferably 30°C to 40°C. Culturing is continued until a maximum of L-amino acids or L-threonine has formed. This target is usually reached within 10 hours to 160 hours.

The analysis of L-amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry 30: 1190-1206 (1958)), or it can take place by reversed phase HPLC as described by Lindroth et al. (Analytical Chemistry 51: 1167-1174 (1979)).

The process according to the invention is used for the fermentative preparation of L-amino acids, such as, for example, L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.

A pure culture of the Escherichia coli K-12 strain DH5 α /pMAK705 was deposited as DSM 13720 on 8th September 2000 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.

The present invention is explained in more detail in the following with the aid of embodiment examples.

The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, ligation, Klenow and alkaline phosphatase treatment are carried out by the method of Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). Unless described otherwise, the transformation of Escherichia coli is carried out by the method of Chung et al.: (Proceedings

of the National Academy of Sciences of the United States of America 86: 2172-2175 (1989)).

The incubation temperature for the preparation of strains and transformants is 37°C. Temperatures of 30°C and 44°C
5 are used in the gene replacement method of Hamilton et al.

Example 1

Construction of the deletion mutation of the aspA gene

Parts of the gene regions lying upstream and downstream of the aspA gene and parts of the 5' and 3' region of the aspA
10 gene are amplified from Escherichia coli K12 using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the aspA gene and sequences lying upstream and downstream in E. coli K12 MG1655 (SEQ ID No. 1, Accession Number
15 AE000486 and AE000487); the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

aspA5'-1: 5' - GCTGCATCAGCACGAAATTC - 3' (SEQ ID No. 3)

aspA5'-2: 5' - CCATTACCATACCGCGAACA - 3' (SEQ ID No. 4)

aspA3'-1: 5' - TGGCAGCAGAAGCAGGTCAG - 3' (SEQ ID No. 5)

20 aspA3'-2: 5' - TAGTCCAGACCGCCAGCAAC - 3' (SEQ ID No. 6)

The chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturer's instructions with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 650 bp in size from the 5' region of
25 the aspA gene region (called aspA5') and a DNA fragment approx. 700 bp in size from the 3' region of the aspA gene region (called aspA3') can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications,
30 Academic Press) with *Taq* polymerase (Boehringer-Mannheim, Eggenstein, Germany). The PCR products are each ligated

with the vector pCR2.1-TOPO (TOPO TA Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturer's instructions and transformed into the E. coli strain TOP10F'. Selection of plasmid-carrying cells
5 takes place on LB agar, to which 50 µg/ml ampicillin are added. After isolation of the plasmid DNA, the vector pCR2.1-TOPOaspA3' is cleaved with the restriction enzymes XbaI and Ecl136II. The aspA3' fragment is isolated after separation in 0.8% agarose gel with the aid of the QIAquick
10 Gel Extraction Kit (QIAGEN, Hilden, Germany). After isolation of the plasmid DNA the vector pCR2.1-TOPOaspA5' is cleaved with the enzymes EcoRV and XbaI and ligated with the aspA3' fragment isolated. The E. coli strain DH5α is transformed with the ligation batch and plasmid-carrying
15 cells are selected on LB agar, to which 50 µg/ml ampicillin are added. After isolation of the plasmid DNA those plasmid in which the mutagenic DNA sequence shown in SEQ ID No. 7 is cloned are detected by control cleavage with the enzymes EcoRI, XbaI and HindIII. One of the plasmids is called
20 pCR2.1-TOPOΔaspA (=pCR2.1-TOPOdeltaaspA).

Example 2

Construction of the replacement vector pMAK705ΔaspA

The ΔaspA allele described in example 1 is isolated from the vector pCR2.1-TOPOΔaspA after restriction with the
25 enzymes HindIII and XbaI and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705 (Hamilton et al., Journal of Bacteriology 171: 4617-4622 (1989)), which has been digested with the enzymes HindIII and XbaI. The ligation batch is transformed in DH5α and plasmid-carrying
30 cells are selected on LB agar, to which 20 µg/ml chloramphenicol are added. Successful cloning is demonstrated after isolation of the plasmid DNA and cleavage with the enzymes HindIII and XbaI. The replacement
35 in Figure 1.

Example 3

Position-specific mutagenesis of the aspA gene in the E. coli strain MG442

The L-threonine-producing E. coli strain MG442 is described
5 in the patent specification US-A- 4,278,765 and deposited
as CMIM B-1628 at the Russian National Collection for
Industrial Microorganisms (VKPM, Moscow, Russia).

For replacement of the chromosomal aspA gene with the
plasmid-coded deletion construct, MG442 is transformed with
10 the plasmid pMAK705 Δ aspA. The gene replacement is carried
out using the selection method described by Hamilton et al.
(Journal of Bacteriology 171: 4617-4622 (1989)) and is
verified by standard PCR methods (Innis et al. (1990) PCR
Protocols. A Guide to Methods and Applications, Academic
15 Press) with the following oligonucleotide primers:

aspA5'-1: 5' - GCTGCATCAGCACGAAATTC - 3' (SEQ ID No. 3)

aspA3'-2: 5' - TAGTCCAGACCGCCAGCAAC - 3' (SEQ ID No. 6)

After replacement has taken place, MG442 contains the form
of the Δ aspA allele shown in SEQ ID No. 8. The strain
20 obtained is called MG442 Δ aspA.

Example 4

Preparation of L-threonine with the strain MG442 Δ aspA

MG442 Δ aspA is multiplied on minimal medium with the
following composition: 3.5 g/l Na₂HPO₄*2H₂O, 1.5 g/l KH₂PO₄,
25 1 g/l NH₄Cl, 0.1 g/l MgSO₄*7H₂O, 2 g/l glucose, 20 g/l agar.
The formation of L-threonine is checked in batch cultures
of 10 ml contained in 100 ml conical flasks. For this,
10 ml of preculture medium of the following composition:
2 g/l yeast extract, 10 g/l (NH₄)₂SO₄, 1 g/l KH₂PO₄, 0.5 g/l
30 MgSO₄*7H₂O, 15 g/l CaCO₃, 20 g/l glucose are inoculated and
the batch is incubated for 16 hours at 37°C and 180 rpm on

- an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of this preculture are transinoculated into 10 ml of production medium (25 g/l $(\text{NH}_4)_2\text{SO}_4$, 2 g/l KH_2PO_4 , 1 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.03 g/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.018 g/l $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, 30 g/l CaCO_3 , 20 g/l glucose) and the batch is incubated for 48 hours at 37°C. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at a measurement wavelength of 660 nm.
- 10 The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction with ninhydrin detection.
- 15 The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	6.0	1.5
MG442 Δ aspA	5.5	1.9

Brief Description of the Figure:

- Figure 1: pMAK705 Δ aspA (= pMAK705deltaaspA)

- 20 The length data are to be understood as approx. data. The abbreviations and designations used have the following meaning:

- cat: Chloramphenicol resistance gene

- 25 • Δ aspA: Targeted deletion of the *aspA* gene in the plasmid pSC101

- aspA5': Part of the 5' region of the aspA gene and the region lying upstream
 - aspA3': Part of the 3' region of the aspA gene and the region lying downstream
- 5 The abbreviations for the restriction enzymes have the following meaning
- EcoRI: Restriction endonuclease from *Escherichia coli*
 - HindIII: Restriction endonuclease from *Haemophilus influenza*
- 10 • XbaI: Restriction endonuclease from *Xanthomonas badrii*

What is claimed is:

1. A process for the preparation of L-amino acids, in particular L-threonine, which comprises carrying out the following steps:
 - 5 a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the aspA gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated,
 - 10 b) concentration of the desired L-amino acid in the medium or in the cells of the microorganisms, and
 - c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof
 - 15 optionally remaining in the product.
2. A process as claimed in claim 1, wherein microorganisms in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
- 20 3. A process as claimed in claim 1, wherein microorganisms in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
4. A process as claimed in claim 1, wherein the expression
- 25 of the polynucleotide which codes for the aspA gene is attenuated, in particular eliminated.
5. A process as claimed in claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide aspA codes are
- 30 reduced.

6. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:
- 5
- 6.1 the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
- 6.2 the pyc gene which codes for pyruvate carboxylase,
- 10
- 6.3 the pps gene which codes for phosphoenol pyruvate synthase,
- 6.4 the ppc gene which codes for phosphoenol pyruvate carboxylase,
- 15
- 6.5 the pntA and pntB genes which code for transhydrogenase,
- 6.6 the rhtB gene which imparts homoserine resistance,
- 6.7 the mqo gene which codes for malate:quinone oxidoreductase,
- 20
- 6.8 the rhtC gene which imparts threonine resistance,
- 6.9 the thrE gene which codes for the threonine export protein,
- 25
- 6.10 the gdhA gene which codes for glutamate dehydrogenase,
- 6.11 the hns gene which codes for the DNA-binding protein HLP-II,

- 6.12 the pgm gene which codes for
phosphoglucomutase,
- 6.13 the fba gene which codes for fructose
biphosphate aldolase,
- 5 6.14 the ptsH gene which codes for the
phosphohistidine protein hexose
phosphotransferase,
- 6.15 the ptsI gene which codes for enzyme I of the
phosphotransferase system,
- 10 6.16 the crr gene which codes for the glucose-
specific IIA component,
- 6.17 the ptsG gene which codes for the glucose-
specific IIBC component,
- 15 6.18 the lrp gene which codes for the regulator of
the leucine regulon,
- 6.19 the mopB gene which codes for 10 Kd chaperone,
- 6.20 the ahpC gene which codes for the small sub-
unit of alkyl hydroperoxide reductase,
- 20 6.21 the ahpF gene which codes for the large sub-
unit of alkyl hydroperoxide reductase,
- 6.22 the cysK gene which codes for cysteine synthase
A,
- 6.23 the cysB gene which codes for the regulator of
the cys regulon,
- 25 6.24 the cysJ gene which codes for the flavoprotein
of NADPH sulfite reductase,
- 6.25 the cysI gene which codes for the haemoprotein
of NADPH sulfite reductase and

6.26 the cysH gene which codes for adenylyl sulfate reductase,

is or are enhanced, in particular over-expressed, are fermented.

5 7. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:

10 7.1 the tdh gene which codes for threonine dehydrogenase,

7.2 the mdh gene which codes for malate dehydrogenase,

15 7.3 the gene product of the open reading frame (orf) yjfa,

7.4 the gene product of the open reading frame (orf) ytfP,

7.5 the pckA gene which codes for phosphoenol pyruvate carboxykinase

20 7.6 the poxB gene which codes for pyruvate oxidase

7.7 the aceA gene which codes for isocitrate lyase,

7.8 the dgsA gene which codes for the DgsA regulator of the phosphotransferase system,

25 7.9 the fruR gene which codes for the fructose repressor,

7.10 the rpoS gene which codes for the sigma³⁸ factor,

7.11 the aceB gene which codes for malate synthase A


7.12 the aceK gene which codes for isocitrate dehydrogenase kinase/phosphatase and

7.13 the ugpB gene which codes for the periplasmic binding protein of the sn-glycerol 3-phosphate transport system

5

is or are attenuated, in particular eliminated or reduced in expression, are fermented.

Figure 1:



SEQUENCE PROTOCOL

	<110>	Degussa AG	
5	<120>	Process for the preparation of L-amino acids using strains of the Enterobacteriaceae family which contain an attenuated aspA gene	
10	<130>	020269 BT	
	<160>	8	
	<170>	PatentIn version 3.1	
15	<210>	1	
	<211>	2280	
	<212>	DNA	
	<213>	Escherichia coli	
20	<220>		
	<221>	CDS	
	<222>	(470)..(1951)	
	<223>	aspA gene	
25	<400>	1	
		gctgcatcag cagcgaattc ttaaagccct gggtacgtac cagtgcacata ccgataactg	60
		acgtgaatat aaccagcacg agggtcagca atacccccaa tacatgggca acctgaataa	120
30		agattgaaat ctcaatatag acataaagga aaatggcaat aaaaggtaac cagcgcgaaag	180
		gtttctcctg taatagcagc cggttaaccc cggctacctg aatggggtgc gaatcgcggt	240
35		tagcttatat tgtggtcatt agcaaaattt caagatgttt gcgcaactat ttttggtagt	300
		aatcccaaag cgggtgatcta tttcacaaat taataattaa ggggtaaaaa ccgacactta	360
		aagtgatcca gattacggta gaaatcctca agcagcatat gatctcgggt attcgggtcga	420
40		tgcaggggat aatcgtcgggt cgaaaaacat tcgaaaccac atatattct gtg tgt tta	478
		Met Cys Leu	
		1	
45		aag caa atc att ggc agc ttg aaa aag aag gtt cac atg tca aac aac	526
		Lys Gln Ile Ile Gly Ser Leu Lys Lys Lys Val His Met Ser Asn Asn	
		5 10 15	
50		att cgt atc gaa gaa gat ctg ttg ggt acc agg gaa gtt cca gct gat	574
		Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu Val Pro Ala Asp	
		20 25 30 35	
		gcc tac tat ggt gtt cac act ctg aga gcg att gaa aac ttc tat atc	622
55		Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu Asn Phe Tyr Ile	
		40 45 50	
		agc aac aac aaa atc agt gat att cct gaa ttt gtt cgc ggt atg gta	670
		Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val Arg Gly Met Val	
		55 60 65	
60		atg gtt aaa aaa gcc gca gct atg gca aac aaa gag ctg caa acc att	718
		Met Thr Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys	
		70 75 80	

	cct aaa agt gta gcg aat gcc atc att gcc gca tgt gat gaa gtc ctg	766
	Pro Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys Asp Glu Val Leu	
	85 90 95	
5	aac aac gga aaa tgc atg gat cag ttc ccg gta gac gtc tac cag ggc	814
	Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp Val Tyr Gln Gly	
	100 105 110 115	
10	ggc gca ggt act tcc gta aac atg aac acc aac gaa gtg ctg gcc aat	862
	Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu Val Leu Ala Asn	
	120 125 130	
15	atc ggt ctg gaa ctg atg ggt cac caa aaa ggt gaa tat cag tac ctg	910
	Ile Gly Leu 135 Leu Met Gly His Gln Lys Gly Glu Tyr Gln Tyr Leu	
	140 145	
20	aac ccg aac gac cat gtt aac aaa tgt cag tcc act aac gac gcc tac	958
	Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr Asn Asp Ala Tyr	
	150 155 160	
25	ccg acc ggt ttc cgt atc gca gtt tac tct tcc ctg att aag ctg gta	1006
	Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu Ile Lys Leu Val	
	165 170 175	
30	gat gcg att aac caa ctg cgt gaa ggc ttt gaa cgt aaa gct gtc gaa	1054
	Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg Lys Ala Val Glu	
	180 185 190 195	
35	ttc cag gac atc ctg aaa atg ggt cgt acc cag ctg cag gac gca gta	1102
	Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu Gln Asp Ala Val	
	200 205 210	
40	ccg atg acc ctc ggt cag gaa ttc cgc gct ttc agc atc ctg ctg aaa	1150
	Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser Ile Leu Leu Lys	
	215 220 225	
45	gaa gaa gtg aaa aac atc caa cgt acc gct gaa ctg ctg ctg gaa gtt	1198
	Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu Leu Leu Glu Val	
	230 235 240	
50	aac ctt ggt gca aca gca atc ggt act ggt ctg aac acg ccg aaa gag	1246
	Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn Thr Pro Lys Glu	
	245 250 255	
55	tac tct ccg ctg gca gtg aaa aaa ctg gct gaa gtt act ggc ttc cca	1294
	Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val Thr Gly Phe Pro	
	260 265 270 275	
60	tgc gta ccg gct gaa gac ctg atc gaa gcg acc tct gac tgc ggc gct	1342
	Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser Asp Cys Gly Ala	
	280 285 290	
65	tat gtt atg gtt cac ggc gcg ctg aaa cgc ctg gct gtg aag atg tcc	1390
	Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala Val Lys Met Ser	
	295 300 305	
70	aaa atc tgt aac gac ctg cgc ttg ctc tct tca ggc cca cgt gcc ggc	1438
	Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly Pro Arg Ala Gly	
	310 315 320	
75	ctg aac gag atc aac ctg ccg gaa ctg cag gcg ggc tct tcc atc atg	1486
	Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly Ser Ser Ile Met	
	325 330 335	

	cca gct aaa gta aac ccg gtt gtt ccg gaa gtg gtt aac cag gta tgc	1534
	Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val Asn Gln Val Cys	
	340 345 350 355	
5	ttc aaa gtc atc ggt aac gac acc act gtt acc atg gca gca gaa gca	1582
	Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met Ala Ala Glu Ala	
	360 365 370	
10	ggc cag ctg cag ttg aac gtt atg gag ccg gtc att ggc cag gcc atg	1630
	Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile Gly Gln Ala Met	
	375 380 385	
15	ttc gaa tcc gtt cac att ctg acc aac gct tgc tac aac ctg ctg gaa	1678
	Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr Asn Leu Leu Glu	
	390 395 400	
20	aaa tgc att aac ggc atc act gct aac aaa gaa gtg tgc gaa ggt tac	1726
	Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val Cys Glu Gly Tyr	
	405 410 415	
20	gtt tac aac tct atc ggt atc gtt act tac ctg aac ccg ttc atc ggt	1774
	Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn Pro Phe Ile Gly	
	420 425 430 435	
25	cac cac aac ggt gac atc gtg ggt aaa atc tgt gcc gaa acc ggt aag	1822
	His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala Glu Thr Gly Lys	
	440 445 450	
30	agt gta cgt gaa gtc gtt ctg gaa cgc ggt ctg ttg act gaa gcg gaa	1870
	Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu Thr Glu Ala Glu	
	455 460 465	
35	ctt gac gat att ttc tcc gta cag aat ctg atg cac ccg gct tac aaa	1918
	Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His Pro Ala Tyr Lys	
	470 475 480	
40	gca aaa cgc tat act gat gaa agc gaa cag taa tcgtacaggg tagtacaat	1971
	Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln	
	485 490	
40	aaaaaaggca cgtcagatga cgtgcctttt ttcttgtgag cagtaactta aaaataacaa	2031
	tctaataatca acttggttaaa aaacaaggaa ggctaatatg ctagtgttag aactcatcat	2091
45	agtttttgctg gcgatcttct tgggcgccag attgggggga ataggtattg gttttgcagg	2151
	cggattgggg gtgctggttc ttgccgctat tggcggttaaa cccggtaaca tcccgttcga	2211
50	tgtcatctcc attatcatgg cggttatcgc cgctatttct gccatgcagg ttgctggcgg	2271
	tctggacta	2280
	<210> 2	
	<211> 493	
55	<212> PRT	
	<213> Escherichia coli	
	<400> 2	
60	Met Cys Leu Lys Gln Ile Ile Gly Ser Leu Lys Lys Lys Val His Met	
	1 5 10 15	
	Ser Asn Asn Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu Val	
	20 25 30	

Pro Ala Asp Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu Asn
 35 40 45
 5 Phe Tyr Ile Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val Arg
 50 55 60
 Gly Met Val Met Val Lys Lys Ala Ala Ala Met Ala Asn Lys Glu Leu
 65 70 75 80
 10 Gln Thr Ile Pro Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys Asp
 85 90 95
 Glu Val Leu Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp Val
 100 105 110
 15 Tyr Gln Gly Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu Val
 115 120 125
 Leu Ala Asn Ile Gly Leu Glu Leu Met Gly His Gln Lys Gly Glu Tyr
 130 135 140
 20 Gln Tyr Leu Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr Asn
 145 150 155 160
 25 Asp Ala Tyr Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu Ile
 165 170 175
 Lys Leu Val Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg Lys
 180 185 190
 30 Ala Val Glu Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu Gln
 195 200 205
 Asp Ala Val Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser Ile
 210 215 220
 35 Leu Leu Lys Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu Leu
 225 230 235 240
 40 Leu Glu Val Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn Thr
 245 250 255
 Pro Lys Glu Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val Thr
 260 265 270
 45 Gly Phe Pro Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser Asp
 275 280 285
 Cys Gly Ala Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala Val
 290 295 300
 50 Lys Met Ser Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly Pro
 305 310 315 320
 55 Arg Ala Gly Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly Ser
 325 330 335
 Ser Ile Met Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val Asn
 340 345 350
 60 Gln Val Cys Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met Ala
 355 360 365
 Ala Glu Ala Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile Gly
 370 375 380
 65

Gln Ala Met Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr Asn
 385 390 395 400
 5 Leu Leu Glu Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val Cys
 405 410 415
 Glu Gly Tyr Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn Pro
 420 425 430
 10 Phe Ile Gly His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala Glu
 435 440 445
 Thr Gly Lys Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu Thr
 450 455 460
 15 Glu Ala Glu Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His Pro
 465 470 475 480
 20 Ala Tyr Lys Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln
 485 490
 <210> 3
 <211> 20
 25 <212> DNA
 <213> artificial sequence
 <220>
 <221> Primer
 30 <222> (1)..(20)
 <223> aspA5'-1
 <400> 3
 35 gctgcatcag cacgaaattc 20
 <210> 4
 <211> 20
 <212> DNA
 40 <213> artificial sequence
 <220>
 <221> Primer
 <222> (1)..(20)
 45 <223> aspA5'-2
 <400> 4
 ccattaccat accggaaca 20
 50 <210> 5
 <211> 20
 <212> DNA
 <213> artificial sequence
 55 <220>
 <221> Primer
 <222> (1)..(20)
 <223> aspA3'-1
 60 <400> 5
 tggcagcaga agcaggtcag 20

5 <210> 6
 <211> 20
 <212> DNA
 <213> artificial sequence

10 <220>
 <221> Primer
 <222> (1)..(20)
 <223> aspA3'-2

 <400> 6
 tagtccagac cgccagcaac 20

15 <210> 7
 <211> 1563
 <212> DNA
 <213> Escherichia coli

20 <220>
 <221> misc_feature
 <222> (1)..(1563)
 <223> mutagenic DNA

25 <220>
 <221> misc_feature
 <222> (1)..(60)
 <223> technical DNA / residues of polylinker sequence

30 <220>
 <221> misc_feature
 <222> (61)..(734)
 <223> parts of the 5' region of the aspA gene and regions lying upstream

35 <220>
 <221> misc_feature
 <222> (735)..(799)
 <223> technical DNA / residues of polylinker sequence

40 <220>
 <221> misc_feature
 <222> (800)..(1511)
 <223> parts of the 3' region of the aspA gene and regions lying downstream

45 <220>
 <221> misc_feature
 <222> (1512)..(1563)
 <223> technical DNA / residues of polylinker sequence

50 <400> 7
 agcttggtac cgagctcgga tccactagta acggccgcca gtgtgctgga attcgccctt 60
 gctgcatcag cagcaaatc ttaaagccct gggtacgtac cagtgcata cggataactg 120
 55 acgtgaatat aaccagcacg agggtcagca atacccccaa tacatgggca acctgaataa 180
 agattgaaat ctcaatatag acataaagga aaatggcaat aaaaggtaac cagcgcaaag 240
 gtttctcctg taatagcagc cgggttaaccc cggtacctg aatgggttgc gaatcgcgtt 300
 60 tagcttatat tgtggtcatt agcaaaatct caagatgttt gcgcaactat ttttggtagt 360
 aatcccaaag cggtgatcta tttcacaat taataattaa ggggtaaaaa ccgacactta 420
 65 aagtgatcca gattacggta gaaatcctca agcagcatat gatctcgggt attcgggtcga 480

	tgccaggggat aatcgctcggc cgaaaaacat tcgaaaccac atatattctg tgtgtttaaa	540
5	gcaaatcatt ggcagcttga aaaagaaggc tcacatgtca aacaacattc gtatcgaaga	600
	agatctgttg ggtaccaggc aagttccagc tgatgcctac tatggtgttc acactctgag	660
	agcgattgaa aacttctata tcagcaacaa caaaatcagt gatattcctg aatttggttcg	720
10	cggatggta atggaagggc gaattctgca gatctcggat ccactagtaa cggccgccag	780
	tgtgctggaa ttcgcccttt ggcagcagaa gcaggtcagc tgcagttgaa cggtatggag	840
15	ccggtcattg gccaggccat gttcgaatcc gttcacattc tgaccaacgc ttgctacaac	900
	ctgctggaaa aatgcattaa cggcatcact gctaacaaag aagtgtgcga aggttacgtt	960
	tacaactcta tcggtatcgt tacttacctg aaccggttca tcggtcacca caacggtgac	1020
20	atcgctggta aaatctgtgc cgaaaccggc aagagtgtac gtgaagtcgt tctggaacgc	1080
	ggctctgtga ctgaagcgga acttgacgat atttctccg tacagaatct gatgcacccg	1140
25	gcttacaag caadacgcta tactgatgaa agcgaacagt aatcgtacag ggtagtaca	1200
	ataaaaaagg cacgtcagat gacgtgcctt tttctctgtg agcagtaact taaaaataac	1260
	aatctaatat caacttgta aaaaacaagg aaggctaata tgctagtgtg agaactcatc	1320
30	atagttttgc tggcgatctt cttgggcgcc agattggggg gaataggtat tggttttgca	1380
	ggcggattgg ggggtgctggc tcttgccgct attggcgta aaccggtaa catcccggtc	1440
35	gatgtcatct ccattatcat ggcggttatc gccgctattt ctgccatgca ggttgctggc	1500
	ggctctggact aaagggcgaa ttctgcagat atccatcaca ctggcggccg ctcgagcatg	1560
	cat	1563
40	<210> 8	
	<211> 653	
	<212> DNA	
	<213> Escherichia coli	
45	<220>	
	<221> misc_feature	
	<222> (1)..(653)	
	<223> mutagenic DNA	
50	<220>	
	<221> misc_feature	
	<222> (1)..(3)	
	<223> start codon of the deltaaspA allele	
55	<220>	
	<221> misc_feature	
	<222> (1)..(205)	
	<223> 5' region of the deltaaspA allele	
60	<220>	
	<221> misc_feature	
	<222> (206)..(270)	
	<223> technical DNA / residues of the polylinker sequence	

<220>
<221> misc_feature
<222> (271)..(653)
<223> 3' region of the deltaaspA allele

5

<220>
<221> misc_feature
<222> (651)..(653)
<223> stop codon of the deltaaspA allele

10

<400> 8
gtgtgttttaa agcaaatcat tggcagcttg aaaaagaaggy ttcacatgtc aaacaacatt 60
cgtatcgaag aagatctgtt ggggtaccagg gaagttccag ctgatgccta ctatgggtgtt 120
15 cacactctga gagcgattga aaacttctat atcagcaaca acaaaatcag tgatattcct 180
gaatttggtc gcggtatggt aatggaaggg cgaattctgc agatctcgga tccactagta 240
20 acggccgccca gtgtgctgga attcgccctt tggcagcaga agcaggtcag ctgcagttga 300
acgttatgga gccggtcatt ggccaggcca tgttcgaatc cgttcacatt ctgaccaacg 360
cttgctacaa cctgtctgga aaatgcatta acggcatcac tgctaacaaa gaagtgtgcg 420
25 aaggttacgt ttacaactct atcggtatcg ttacttacct gaaccggtc atcggtcacc 480
acaacggtga catcgtgggt aaaatctgtg ccgaaaccgg taagagtgta cgtgaagtcg 540
30 ttctggaacg cgtctctgtg actgaagcgg aacttgacga tattttctcc gtacagaatc 600
tgatgcaccc ggcttacaaa gcaaaacgct atactgatga aagcgaacag taa 653

35

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/008603 A3

(51) International Patent Classification⁷: C12P 13/08,
13/12, 13/14, 13/06, 13/10, 13/20, 13/22, 13/24

(21) International Application Number: PCT/EP02/07351

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
101 35 051.1 18 July 2001 (18.07.2001) DE
60/306,867 23 July 2001 (23.07.2001) US

(71) Applicant (for all designated States except US): DE-
GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düssel-
dorf (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): HERMANN, Thomas
[DE/DE]; Zirkonstrasse 8, 33739 Bielefeld (DE).

(74) Common Representative: DEGUSSA AG; Intellectual
Property Management, Patents and Trademarks, Location
Hanau, P.O.Box 13 45, 63403 Hanau (VN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only


Published:

— with international search report

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEA
FAMILY WHICH CONTAIN AN ATTENUATED ASPA GENE



(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the aspA gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated, b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.

WO 03/008603 A3



(88) Date of publication of the international search report:
31 July 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07351

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12P13/08 C12P13/12 C12P13/14 C12P13/06 C12P13/10
C12P13/20 C12P13/22 C12P13/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EP0-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WOODS S A ET AL: "DIFFERENTIAL ROLE OF THE ESCHERICHIA COLI FUMARASES AND FNR-DEPENDENT EXPRESSION OF FUMARASE B AND ASPARTASE" FEMS (FEDERATION OF EUROPEAN MICROBIOLOGICAL SOCIETIES) MICROBIOLOGY, vol. 48, no. 1-2, 1987, pages 219-224, XP008018171 1987 ISSN: 0378-1097 the whole document --- -/-	1-7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

11 June 2003

Date of mailing of the international search report

24/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kools, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07351

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MENKEL E ET AL: "INFLUENCE OF INCREASED ASPARTATE AVAILABILITY ON LYSINE FORMATION BY A RECOMBINANT STRAIN OF CORYNEBACTERIUM-GLUTAMICUM AND UTILIZATION OF FUMARATE" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 55, no. 3, 1989, pages 684-688, XP008017685 ISSN: 0099-2240 abstract	1-7
A	US 4 347 318 A (MIWA KIYOSHI ET AL) 31 August 1982 (1982-08-31) the whole document	1-7
A	CHAO YUN-PENG ET AL: "Selective production of L-aspartic acid and L-phenylalanine by coupling reactions of aspartase and aminotransferase in Escherichia coli." ENZYME AND MICROBIAL TECHNOLOGY, vol. 27, no. 1-2, July 2000 (2000-07), pages 19-25, XP002243820 ISSN: 0141-0229 the whole document	1-7
A	VIPOND RICHARD ET AL: "Defined deletion mutants demonstrate that the major secreted toxins are not essential for the virulence of Aeromonas salmonicida." INFECTION AND IMMUNITY, vol. 66, no. 5, May 1998 (1998-05), pages 1990-1998, XP002243821 ISSN: 0019-9567 abstract	1-7
A	LANDGRAF J R ET AL: "THE ROLE OF H-NS IN ONE CARBON METABOLISM" BIOCHIMIE, MASSON, PARIS, FR, vol. 76, no. 10/11, 1994, pages 1063-1070, XP008014239 ISSN: 0300-9084 page 1064, column 1, last paragraph	1-7
E	WO 03 008616 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008604 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008602 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07351

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 03 008600 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7</p>	7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/07351

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4347318	A	31-08-1982	JP 1029559 B	12-06-1989
			JP 1552063 C	23-03-1990
			JP 55131397 A	13-10-1980
			DE 3012921 A1	23-10-1980
			FR 2453216 A1	31-10-1980
			GB 2049670 A , B	31-12-1980
WO 03008616	A	30-01-2003	DE 10135051 A1	06-02-2003
			WO 03008600 A2	30-01-2003
			WO 03008602 A2	30-01-2003
			WO 03008603 A2	30-01-2003
			WO 03008604 A2	30-01-2003
			WO 03008616 A2	30-01-2003
WO 03008604	A	30-01-2003	DE 10135051 A1	06-02-2003
			WO 03008600 A2	30-01-2003
			WO 03008602 A2	30-01-2003
			WO 03008603 A2	30-01-2003
			WO 03008604 A2	30-01-2003
			WO 03008616 A2	30-01-2003
WO 03008602	A	30-01-2003	DE 10135051 A1	06-02-2003
			WO 03008600 A2	30-01-2003
			WO 03008602 A2	30-01-2003
			WO 03008603 A2	30-01-2003
			WO 03008604 A2	30-01-2003
			WO 03008616 A2	30-01-2003
WO 03008600	A	30-01-2003	DE 10135051 A1	06-02-2003
			WO 03008600 A2	30-01-2003
			WO 03008602 A2	30-01-2003
			WO 03008603 A2	30-01-2003
			WO 03008604 A2	30-01-2003
			WO 03008616 A2	30-01-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.